Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study


Targeted monoclonal antibodies (MoAbs) have become a promising treatment option for patients with cancer. However, there is a risk of developing infusion reactions (IRs) with MoAbs. This study was conducted to evaluate the impact of IRs on staff time and costs among patients receiving an initial infusion of cetuximab (Erbitux®) and rituximab (Rituxan®). A… (More)
DOI: 10.1007/s00520-008-0474-5

6 Figures and Tables


  • Presentations referencing similar topics